<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129670">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414010</url>
  </required_header>
  <id_info>
    <org_study_id>2010-P-000319</org_study_id>
    <nct_id>NCT01414010</nct_id>
  </id_info>
  <brief_title>Effects of Pre-, Pro- &amp; Anti-biotics on Gut Microbiota</brief_title>
  <official_title>Effects of Mushroom Extract, S Boulardii and Amoxicillin on the Human Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hong Kong Association for Health Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Integrated Chinese Medicine Holdings</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and contrast the effects of a prebiotic (Trametes
      Versicolor), a probiotic (Saccharomyces boulardii) and an antibiotic (amoxicillin) on the
      gut microbiota of healthy volunteers. It is expected that treatment will result in the rapid
      and reproducible alterations in fecal microbiota that will spontaneously reverse in the
      weeks after treatment is discontinued.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microbiome quantity</measure>
    <time_frame>Days -28 to -7, 0, 10, 14, 21, 28, 56</time_frame>
    <description>Change in total numbers of bacteria in stool samples over the course of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in microbiome diversity</measure>
    <time_frame>Days -28 to -7, 0, 10, 14, 21, 28, 56</time_frame>
    <description>Change in total numbers of bacterial strains in stool samples as determined by operational taxonomic units over the course of the study</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Human Gut Microbiota</condition>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group, no intervention given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Trametes versicolor extract</intervention_name>
    <description>1,200 mg, 3 times daily on an empty stomach for 14 days</description>
    <arm_group_label>Prebiotic</arm_group_label>
    <other_name>turkey tail</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Saccharomyces boulardii</intervention_name>
    <description>250 mg, 3 times daily on an empty stomach for 14 days</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>250 mg 3 times daily at least 1 hour before meals for 7 days</description>
    <arm_group_label>Antibiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 39 years (male or female)

          -  Good general health

          -  Able to comply with study requirements and to provide informed consent

          -  For women of childbearing potential

          -  A negative urine pregnancy test immediately prior to starting the study treatment

          -  Agreement to comply with approved methods of contraception during the period of
             active study treatment (not required during follow-up)

        Exclusion Criteria:

          -  Any diagnosed autoimmune disease

          -  History of organ transplantation

          -  Known chronic or recurrent systemic disorder associated with immunocompromise

          -  A history of allergy or hypersensitivity to mushroom or mushroom extract, brewer's or
             baker's yeast or to penicillins or cephalosporins (including amoxicillin).

          -  History of severe allergic reaction (requiring hospital admission and/or the
             administration of parenteral medication or associated with dyspnoea, wheezing,
             hypotension, loss of consciousness).

          -  Systemic antibacterial therapy during the 3 months prior to study enrollment

          -  New prescription medications during the 4 weeks prior to study enrollment

          -  Prescription or OTC medications or supplements that are known to alter gut function
             or microflora (i.e. acid antisecretory drugs, probiotics) during the 4 weeks prior to
             study enrollment

          -  Active gastrointestinal or metabolic disease

          -  Prior gastrointestinal surgery (apart from appendectomy or cholecystectomy)

          -  History of chronic constipation with passage of fewer than 3 spontaneous bowel
             movements per week on average or chronic or recurrent diarrhea with spontaneous bowel
             movements more often than 3 times daily

          -  Any condition or personal circumstance that, in the opinion of the investigator,
             renders the subject unlikely or unable to comply with the full study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciaran P Kelly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <lastchanged_date>March 7, 2012</lastchanged_date>
  <firstreceived_date>August 5, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>gut microbiota</keyword>
  <keyword>gut microbiome</keyword>
  <keyword>prebiotic</keyword>
  <keyword>probiotic</keyword>
  <keyword>antibiotic</keyword>
  <keyword>antibiotic-associated diarrhea</keyword>
  <keyword>intestinal bacterial overgrowth</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
